Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study
Authors' conclusion
Among retrospectively reported pre-treatment concerns, fear of side effects, treatment costs and injection anxiety were most strongly associated with lower functioning and well-being, whereas moral or psychosocial concerns showed no independent associations after multivariable adjustment.
Study context
- Population
- Adults undergoing incretin-based pharmacotherapy for obesity, treated with three different incretin-based medications; median age 39 years (IQR 33–47), 79.1% women, median BMI 36.3 kg/m² (IQR 32.2–42.3)
- Participants
- 411 adults
- Outcome
- Associations of pre-treatment concerns with functioning and well-being (TRIM-Weight total score)
Main finding
As reported in the abstract
Fear of side effects: β (95% CI), lower functioning and well-being
−3.53
−4.05 to −3.01
Concerns about cost: β (95% CI), lower functioning and well-being
−0.92
−1.37 to −0.47
Injection anxiety: β (95% CI), lower functioning and well-being
−0.67
−1.16 to −0.18
Doubts regarding effectiveness: β (95% CI), small positive association
0.61
0.03–1.19
Observational data: associations, not effects.
Further findings
TRIM-Weight total score
- Median TRIM-Weight total score (IQR)
- 68.2 (64.0-73.4)
Previous weight-loss attempts
- Had attempted weight loss
- 95.1%
- Combined diet and physical activity
- 71.8%
- Intermittent fasting
- 69.6%
- Digital tracking tools
- 65.7%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →